Searchlight Pharma Inc., headquartered in Montreal, aspires to become a leading Canadian-based specialty healthcare company through best-in class execution of the search, acquisition, commercialization, and focused development of innovative and unique specialty healthcare products that improve life-long human health and wellness. With a core focus on women’s health, urology, and specialty therapeutics, our team is committed to improving people’s lives by bringing the right products to market. Our trusted brands include Divigel®, Addyi®, Estragyn Vaginal Cream™, Mona Lisa® IUDs, Bulkamid®, Rocaltrol® and Enablex® – visit our booth and www.searchlightpharma.com to learn more.
Mithra and Searchlight Pharma announced on March 8th, 2021 that Health Canada has approved Nextstellis®, the first and only combined oral contraceptive (COC) product based on the unique native estrogen estetrol (E4). Once launched, E4 will be the first new estrogen in a COC in the Canadian market in over half a century, and will be the only COC alternative to ethinyl estradiol-based COC pills in Canada.